Latest Breaking News On - Phase 2 molto trial - Page 1 : comparemela.com

The combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter transformation, according to data from the phase 2 MOLTO trial.

Anna maria frustaciNiguarda cancer centerInternational conference on malignant lymphomaAnnual international conferenceAnn arborChronic lymphocytic leukemiaNon hodgkin lymphomaRichters transformationPhase 2 molto trial